Acute Myeloid Leukemia (AML) is an aggressive blood cancer with a poor prognosis, especially for patients with relapse or treatment resistance (R/R AML). Current treatment options are limited, highlighting the urgent need for better therapies and broader access to quality care. The IMPACT-AML project addresses these challenges with an inclusive, patient-centered approach to improve outcomes for R/R AML patients in Europe and beyond.
IMPACT-AML's primary goal is to build a collaborative framework where all R/R AML patients can be enrolled in registries or trials, regardless of background. This framework is supported by the STREAM platform, which standardizes and analyzes clinical data, facilitating Randomized Pragmatic Clinical Trials (RPCT) to improve treatment strategies and guide future care.
The project also focuses on biobanking, developing SOPs for tissue storage and MRD analysis to support translational research. A key aspect of IMPACT-AML is the RPCT, comparing low- and high-intensity rescue therapies, involving 340 patients across Europe for a representative dataset.
IMPACT-AML addresses vulnerable groups, including pediatric patients and the elderly, ensuring they are not overlooked. Patient and caregiver involvement is central, with partners like ALAN actively engaging to enhance patient experiences.
The project also aims to make AML care accessible across different healthcare systems, including lower-resource settings. Telemedicine pilots in countries like Ukraine and Tanzania extend AML care beyond Europe, promoting collaboration and reducing health disparities.
Through a network of clinical partners, biotech companies, patient organizations, and regulatory bodies, IMPACT-AML aims to set new standards in AML treatment and foster open science through data sharing and collaboration.
